Hepatitis Monthly

Published by: Kowsar

Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study

Jian Liang 1 , Man Jun Jiang 1 , Xin Deng 1 , * and Xiao Xiao Zhou 1
Authors Information
1 Department of Hepatology Ruikang Hospital, Guangxi Traditional Chinese Medical University, Nanning, China
Article information
  • Hepatitis Monthly: May 2013, 13 (6); e7862
  • Published Online: May 23, 2013
  • Article Type: Research Article
  • Received: August 22, 2012
  • Revised: February 6, 2013
  • Accepted: February 27, 2013
  • DOI: 10.5812/hepatmon.7862

To Cite: Liang J, Jiang M J, Deng X, Xiao Zhou X. Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study, Hepat Mon. 2013 ;13(6):e7862. doi: 10.5812/hepatmon.7862.

Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2): 507-39[DOI][PubMed]
  • 2. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005; 9(2): 191-211[DOI][PubMed]
  • 3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[PubMed]
  • 4. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009; 49(5 Suppl)[DOI][PubMed]
  • 5. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev. 2006; (2)[DOI][PubMed]
  • 6. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009; 50(2): 227-42[DOI][PubMed]
  • 7. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341(17): 1256-63[DOI][PubMed]
  • 8. Gramenzi A, Loggi E, Micco L, Cursaro C, Fiorino S, Galli S, et al. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. J Viral Hepat. 2011; 18(10)-74[DOI][PubMed]
  • 9. Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, et al. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int. 2011; 5(2): 654-63[DOI][PubMed]
  • 10. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348(9): 808-16[DOI][PubMed]
  • 11. Dienstag J, Easley C, Kirkpatrick P. Telbivudine. Nat Rev Drug Discov. 2007; 6(4): 267-8[DOI][PubMed]
  • 12. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007; 147(11): 745-54[PubMed]
  • 13. Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int. 2011; 31(5): 676-84[DOI][PubMed]
  • 14. Hann HW. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opin Pharmacother. 2010; 11(13): 2243-9[DOI][PubMed]
  • 15. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology. 2008; 47(2): 447-54[DOI][PubMed]
  • 16. Lv GC, Ma WJ, Ying LJ, Jin X, Zheng L, Yang YD. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol. 2010; 16(32): 4095-9[PubMed]
  • 17. FDA notifications. Entecavir is approved for chronic hepatitis B infection in adults. AIDS Alert. 2005; 20(7): 83-4[PubMed]
  • 18. Keeffe EB. Treatment of chronic hepatitis B with entecavir: High potency and absent viral resistance with 1 year of therapy. Evidence-Based Gastroenterol. 2006; 3(7): 79-80
  • 19. Gonzalez SA, Keeffe EB. Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2009; 7(9): 1053-62[DOI][PubMed]
  • 20. Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist. 2011; 4: 55-64[DOI][PubMed]
  • 21. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009; 49(5): 1503-14[DOI][PubMed]
  • 22. Zhang X, Lin SM, Ye F, Chen TY, Liu M, Chen YR, et al. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients. J Viral Hepat. 2011; 18(7)-90[DOI][PubMed]
  • 23. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354(10): 1001-10[DOI][PubMed]
  • 24. Lai CL, Gane E, Chao-Wei H, Thongsawat S, Wang Y, Chen Y. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology. 2006; 44
  • 25. Zhu FY. Twenty-four weeks results of entecavir versus telbivudine treatments in patients with HBeAg-positive chronic hepatitis B. Clin J Med Offic. 2011; 1(39)
  • 26. Shi KQ, Zhang DZ, Guo SH, He H, Wang ZY, Shi XF, et al. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China]. Zhonghua Gan Zang Bing Za Zhi. 2008; 16(9): 641-5[PubMed]
  • 27. Suh DJ, Um SH, Herrmann E, Kim JH, Lee YS, Lee HJ, et al. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother. 2010; 54(3): 1242-7[DOI][PubMed]
  • 28. Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Clin Ther. 2010; 32(4): 649-58[DOI][PubMed]
  • 29. Huang J, Chen XP, Chen XF, Chen WL, Chen R, Ma XJ, et al. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(3): 178-81[DOI][PubMed]
  • 30. Xu HX, Yu YX, Zhang MX, Wu YP, Liu XX, Chen Y. Application of telbivudine and entecavir in the treatment of patients with HBeAg-positive chronic hepatitis B. J Clin Hepatol. 2011; 4(14): 265-7
  • 31. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.4.
  • 32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-88[PubMed]
  • 33. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4): 719-48[PubMed]
  • 34. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4): 1088-101[PubMed]
  • 35. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629-34[PubMed]
  • 36. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991; 337(8746): 867-72[PubMed]
  • 37. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986; 4(10): 1529-41[PubMed]
  • 38. Sterling TD, Rosenbaum WL, Weinkam JJ. Publication decisions revisited: The effect of the outcome of statistical tests on the decision to publish and vice versa. Am Stat. 1995; 49(1): 108-12
  • 39. Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 2006; 28(2): 184-203[DOI][PubMed]
  • 40. Almeida AM, Ribeiro AQ, Padua CA, Brandao CM, Andrade EI, Cherchiglia ML, et al. [The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review]. Rev Soc Bras Med Trop. 2010; 43(4): 440-51[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader